Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Breast Neoplasms 1Barrett Esophagus 1

Interventions

Specimen Handling 6Colposcopy 5Human Papillomavirus DNA Tests 4fludarabine phosphate 2fludarabine 2aldesleukin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Cyclophosphamide 2polyphenon E 1human papillomavirus vaccine, L1 type 16, 18 1adacel 1Vaginal Smears 1Tetanus Toxoid 1Respiratory Function Tests 1Radiotherapy 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Ipilimumab 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Granisetron 1Electrocardiography 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Papillomavirus Infections × polyphenon E × Clear all
NCT00303823 2015-05-05

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
98 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡